JR4-187 是一种具有口服活性的铜依赖性抗癌剂,可下调癌细胞中参与氧化磷酸化、MYC 靶标及 E2F 靶标的基因,同时上调参与 TNF-α 信号通路、p53 通路及 KRAS 信号通路的基因并下调 CTR1 蛋白,还可诱导 ROS 产生、细胞凋亡 (apoptosis) 及铜依赖性细胞毒性,对 KRAS 突变型癌细胞具有选择性细胞毒性,在胰腺癌小鼠模型中具有良好的耐受性,可用于胰腺导管腺癌、结肠癌、直肠癌等癌症的相关研究。
产品编号: MS-L10753 CAS No.: 2446965-01-9 分子式: C23H25FN6O2 分子量: 436.48
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

JR4-187 是一种具有口服活性的铜依赖性抗癌剂,可下调癌细胞中参与氧化磷酸化、MYC 靶标及 E2F 靶标的基因,同时上调参与 TNF-α 信号通路、p53 通路及 KRAS 信号通路的基因并下调 CTR1 蛋白,还可诱导 ROS 产生、细胞凋亡 (apoptosis) 及铜依赖性细胞毒性,对 KRAS 突变型癌细胞具有选择性细胞毒性,在胰腺癌小鼠模型中具有良好的耐受性,可用于胰腺导管腺癌、结肠癌、直肠癌等癌症的相关研究。

生物实验数据

生物活性 JR4-187 is an orally active copper-dependent anticancer agent that downregulates genes involved in oxidative phosphorylation, MYC targets, and E2F targets while upregulating genes involved in TNF-α signaling, p53 pathway, and KRAS signaling, and downregulates CTR1 protein; it induces ROS production, apoptosis, and copper-dependent cytotoxicity, exhibits selective cytotoxicity against KRAS-mutant cancer cells, is well tolerated in mouse models of pancreatic cancer, and can be used for research on pancreatic ductal adenocarcinoma, colon cancer, rectal cancer, and other cancers.
体外研究
(In Vitro)

JR4-187 (2 μM; 24 h) 可下调 HCT116 细胞中参与氧化磷酸化、MYC 靶标及 E2F 靶标的基因,同时上调参与 TNF-α 信号通路、p53 通路及 KRAS 信号通路的基因。
JR4-187 (2.5-15 μM; 4-24 h) 可显著下调 HCT116、MIA PaCa-2、PANC1 和 BXPC3 细胞中 MYC、NDUFS7 蛋白的表达。
JR4-187 (0.03-1 μM; 6 days) 在 HCT116 结肠癌细胞中可产生细胞毒性作用 (与 Danazol (MS-P50679)、Metformin (MS-K91034)、IACS-010759 (MS-M78469)、Rotenone (MS-D42728)、DX2-201 (MS-W96249)、DX3-213B (MS-K50640)、AGB-374 联用)、拮抗作用 (与 MYCi361 (MS-Z07152)、10058-F4 (MS-D52088)、MYCMI-6 (MS-Z64494) 联用)。
JR4-187 (10 μM; 24 h) 可显著下调 HCT116 和 MIA PaCa-2 细胞中 CTR1 蛋白的表达。
JR4-187 (2.5 μM; 24 h) 与 5 μM AGB-374 (MS-S62348) 联合作用可在 HCT116 结肠癌细胞中协同下调 MYC 和 NDUFS7 的蛋白表达。
JR4-187 (Compound 39) 可强效抑制 KRAS 突变型胰腺癌和结肠癌细胞的增殖,在 SU.86.86 细胞 (IC50 = 0.8 μM) 和 MIA PaCa-2 细胞 (IC50 = 1.9 μM) 中活性最高,在 KRAS 野生型 BxPC-3 细胞中活性较低。
JR4-187 (0-10 μM; 6 days) 具有铜依赖性细胞毒性,在 MIA PaCa-2 和 HCT116 细胞中与 CuSO4 表现出强协同作用,且在铜螯合剂 TTM (MS-R55382 ) 存在下活性降低。
JR4-187 (0-5 μM; 6 days) 与 COX2 抑制剂 Celecoxib (MS-N33697) 和 Rofecoxib (MS-T31275) 在抑制 HCT116、MIA PaCa-2 和 BxPC-3 细胞的集落形成方面表现出强协同作用。
JR4-187 (0-1 μM; 6 days) 在 HCT116 和 MIA PaCa-2 细胞中可诱导 ROS 依赖性细胞死亡。
JR4-187 (0-10 μM; 1-6 days) 可通过细胞凋亡和坏死性凋亡部分诱导 MIA PaCa-2 和 HCT116 细胞死亡。

Western Blot Analysis

Cell Line: HCT116 human colon cancer cells
Concentration: 10 μM
Incubation Time: 4 h; 24 h
Result: Significantly downregulated MYC protein levels relative to control cells.

Western Blot Analysis

Cell Line: MIA PaCa-2 and BXPC3 human pancreatic cancer cells
Concentration: 10 μM
Incubation Time: 24 h
Result: Decreased MYC protein abundance in both MIA PaCa-2 and BXPC3 cells.

Western Blot Analysis

Cell Line: HCT116 human colon cancer cells, MIA PaCa-2 and PANC1 human pancreatic cancer cells
Concentration: 2.5, 5, 7.5, 10, 15 μM
Incubation Time: 24 h
Result: Caused a dose-dependent reduction in MYC protein levels in HCT116, MIA PaCa-2, and PANC1 cells.\nCaused a dose-dependent reduction in NDUFS7 protein levels in HCT116, MIA PaCa-2, and PANC1 cells.

Cell Cytotoxicity Assay

Cell Line: HCT116 human colon cancer cells
Concentration: 0.03, 0.1, 0.3, 1 μM
Incubation Time: 6 days
Result: Showed strong cytotoxic synergy with Danazol.
Showed strong antagonism with MYCi361, 10058-F4, and MYCMI-6.
Showed no significant interaction with 10074-G5.
Showed significant synergy with metformin, IACS-010759, and Rotenone.
Showed weak synergy with 2-DG.
Showed significant synergy with DX2-201, DX3-213B, and AGB-374.

Western Blot Analysis

Cell Line: HCT116 human colon cancer cells and MIA PaCa-2 human pancreatic cancer cells
Concentration: 10 μM
Incubation Time: 24 h
Result: Caused a marked decrease in CTR1 protein levels in both HCT116 and MIA PaCa-2 cells, with a log10 fold change of ~-0.3 in HCT116 cells and ~-0.15 in MIA PaCa-2 cells.

Western Blot Analysis

Cell Line: HCT116 human colon cancer cells
Concentration: 2.5 μM (alone and in combination with 5 μM AGB-374)
Incubation Time: 24 h
Result: Led to synergistic downregulation of both MYC and NDUFS7 protein levels in HCT116 cells, compared to monotherapy with either agent.

Cell Cytotoxicity Assay

Cell Line: MIA PaCa-2, HCT116
Concentration: 0, 0.018, 0.05, 0.16, 0.5 μM/0, 0.03, 0.1, 0.3, 1 μM/0. 0.3. 1.1, 3.3, 10 μM
Incubation Time: 6 days
Result: Showed strong synergy with copper sulfate (CuSO4) in both cell lines, as measured by the HSA model in Combenefit software.
Exhibited significantly reduced cytotoxic activity when combined with copper chelator ammonium Tetrathiomolybdate (TTM).

Cell Proliferation Assay

Cell Line: HCT116, MIA PaCa-2, BxPC-3
Concentration: 0, 0.03, 0.1, 0.3, 1 μM (HCT116 with Celecoxib); 0, 0.018, 0.05, 0.16, 0.5 μM (MIA PaCa-2 with Celecoxib; MIA PaCa-2 with Rotecoxib); 0, 0.03, 0.1, 0.3, 1 μM (HCT116 with Rotecoxib); 0, 0.18, 0.5, 1.6, 5 μM ( BxPC-3 with Celecoxib)
Incubation Time: 6 days
Result: Showed strong synergy with celecoxib across all three cell lines, as measured by the HSA model in Combenefit software.
Exhibited strong synergy with rotecoxib in HCT116 and MIA PaCa-2 cells, as measured by the HSA model in Combenefit software.

Cell Cytotoxicity Assay

Cell Line: HCT116, MIA PaCa-2
Concentration: 0, 0.03, 0.1, 0.3, 1 μM (HCT116); 0, 0.018, 0.05, 0.16, 0.5 μM (MIA PaCa-2)
Incubation Time: 6 days
Result: Induced cell death that was rescued by pretreatment with ROS scavenger N-acetyl cysteine (NAC) in both cell lines.

Cell Cytotoxicity Assay

Cell Line: MIA PaCa-2, HCT116
Concentration: 0, 0.018, 0.05, 0.16, 0.5 μM (MIA PaCa-2 with Z-VAD-FMK; MIA PaCa-2 with Necrostatin-1); 0, 0.03, 0.1, 0.3, 1 μM (HCT116 with Z-VAD-FMK); 0, 0.07, 0.2, 0.6, 2 μM (HCT116 with necrostatin-1); 10 μM (WB for apoptosis markers); 10 μM (WB for necroptosis markers)
Incubation Time: 6 days/48 h (WB for apoptosis markers); 48 h (WB for necroptosis markers)
Result: Induced cell death that was partially rescued by apoptosis inhibitor Z-VAD-FMK and necroptosis inhibitor necrostatin-1 in both cell lines.
Increased cleaved PARP, cleaved caspase-9, cleaved caspase-3 (apoptosis markers) in cells treated for 48 h, as confirmed by Western blot analysis.
Increased phospho-RIP3 (necroptosis marker) in cells treated for 1 h, as confirmed by Western blot analysis.
体内研究
(In Vivo)

JR4-187 (20-40 mg/kg;腹腔注射;每日;第 1-28 天) 在携带有 PAN02 胰腺癌同系异体移植物的雌性 C57BL/6 小鼠中具有良好的耐受性。

Animal Model: C57BL/6 (female)
Dosage: 40 mg/kg (days 1-20); 20 mg/kg (days 21-28)
Administration: i.p.; daily; days 1-28
Result: Showed no significant loss in body weight.

化学信息

分子量 436.48
分子式 C23H25FN6O2
CAS No. 2446965-01-9

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础